The ribosomal protein L14 (RPL14) is a component of the 60S ribosomal subunit, playing a critical role in protein synthesis by facilitating ribosome assembly and mRNA translation. Beyond its canonical function, RPL14 has been implicated in extra-ribosomal activities, including cell cycle regulation, apoptosis, and interactions with specific RNAs or proteins. Dysregulation of RPL14 expression is associated with various diseases, such as cancers (e.g., colorectal, hepatocellular carcinoma) and Diamond-Blackfan anemia, a ribosomopathy linked to mutations in ribosomal proteins.
RPL14 antibodies are essential tools for studying these biological and pathological processes. They enable the detection and quantification of RPL14 in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Researchers also use these antibodies to explore RPL14's interaction partners or subcellular localization, particularly in contexts of ribosome biogenesis defects or stress responses.
Commercially available RPL14 antibodies are typically raised in hosts like rabbits or mice, with clonality options (monoclonal/polyoclonal) varying by supplier. Validation data, including knockout controls or cross-reactivity assessments, are crucial for ensuring specificity, as ribosomal proteins often share high homology across family members. Recent studies leveraging RPL14 antibodies have shed light on its role in tumor progression and therapeutic resistance, highlighting its potential as a biomarker or target in precision medicine.